Preparing to Exercise

Article

What to know before beginning an exercise program

Everyone can do some type of activity. But it’s important that patients keep in mind a few general precautions before exercising during cancer treatment.

Patients who were already active may have to slow down a bit during treatment and perhaps not exercise as intensely as they had before. They should assess how they feel and avoid pushing themselves. It’s important for patients to communicate with their healthcare providers about their planned physical activities before they begin.

People who were sedentary before should start slowly, adding more intensity and frequency as they are able. Patients should consider how active they were before treatment and adjust accordingly.

Side effects of treatment can determine the most appropriate type of exercise. For example, someone with neuropathy may have numb toes, which would make riding a stationary bike a better choice than walking on a treadmill. Patients experiencing lymphedema have long been discouraged from upper body strength training or vigorous activity, but a number of clinical trials have shown that not only are these activities safe for these individuals, but also may actually reduce the incidence and severity of lymphedema. Patients must talk to their doctors to determine what is safe.

Patients who are undergoing frequent chemotherapy treatments may have lower immune function and should avoid working out in public places, such as gyms. People who are having skin reactions from radiation treatments and those with open wounds or catheters should avoid swimming in chlorinated pools.

An upper-body port may necessitate temporarily avoiding upper-body strength training. Patients with advanced disease who experience limitations due to bone metastases should discuss exercise with their healthcare provider and generally use pain or discomfort as a guide for what type of activity to avoid.

[Staying Active During Treatment]

Related Videos
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Related Content